In this context, the PRIME trial (NCI10264) was recently proposed, as a proof of concept, biomarker-driven, phase II clinical trial to evaluate the overall response of IDH1/IDH2-mutant refractory/relapsed AML and MDS to PARP inhibitor monotherapy with olaparib [178]. This evidence concerns the gene IDH1 and acute myeloid leukemia.